CPD Managing Patients With Asthma Across the Age Ranges

Authors: Roland Buhl, MD, PhD; Eckard Hamelmann, MD; Nikolaos Papadopoulos, MD, PhD, FAAAI, FRCP; Christian Vogelberg, MD

CPD Released: 6/10/2019

Valid for credit through: 6/10/2020

START ACTIVITY

Credits Available

Non-US Physicians – maximum of 0.50 CPD

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US allergists and clinical immunologists, pediatricians, and primary care physicians.

The goal of this activity is to improve physicians’ education regarding current treatment guidelines for asthma, the role of anticholinergic therapy, and best practice in the treatment of pediatric and adult patients to optimize clinical outcomes.

Upon completion of this activity, participants will:

Have increased knowledge regarding the

Similarities and differences in asthma diagnosed in children and adults

Factors that may lead to poor asthma control in pediatric and adult patients

Most recent treatment guidelines and recommendations regarding additional therapy for severe or uncontrolled asthma in both pediatric and adult patients

Clinical efficacy and safety data supporting the use of long-acting muscarinic receptor antagonists in adult and pediatric patients with asthma

Demonstrate greater confidence in their ability to

Make informed clinical decisions regarding the use of targeted therapy for moderate to severe asthma in adult and pediatric patients

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Roland Buhl, MD, PhD

Professor
Pulmonary Department
Mainz University Hospital
Mainz, Germany

Disclosure: Roland Buhl, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Pharmaceuticals, Inc. ; Novartis Pharmaceuticals Corporation; Roche Holdings AG; TEVA PHARMACEUTICALS USA
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Pharmaceuticals, Inc.; Cipia; Novartis Pharmaceuticals Corporation; Roche Holdings AG; TEVA PHARMACEUTICALS USA
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; and Roche Holdings AG

Faculty

Eckard Hamelmann, MD

EvKB, Klinik für Kinder- und Jugendmedizin
Bielefeld, Germany

Disclosure: Eckard Hamelmann, MD, has disclosed no relevant financial relationships.

Nikolaos Papadopoulos, MD, PhD, FAAAI, FRCP

Professor
Allergy & Paediatric Allergy
University of Manchester
Manchester, United Kingdom

Disclosure: Nikolaos Papadopoulos, MD, PhD, FAAAI, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; HAL; Mylan Laboratories Inc.; Menarini; Novartis Pharmaceuticals Corporation; Nutricia; Sanofi
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; HAL; Menarini; Merck Sharp & Dohme Corp; Mylan Laboratories Inc.; Novartis Pharmaceuticals Corporation; Nutricia
Received grants for clinical research from: Gerolymatos; Menarini; Nutricia; Vian

Christian Vogelberg, MD

Professor
Pediatric Pneumology and Allergology
Universitätsklinikum Carl Gustav Carus
Klinik und Poliklinik für Kinder- und Jugendmedizin
Dresden, Germany

Disclosure: Christian Vogelberg, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allergopharma; Bencard Allergy; DBV Technologie SA; Novartis Pharmaceuticals Corporation; Sanofi/Genzyme Corporation
Served as a speaker or a member of a speakers bureau for: ALK Abello; Allergopharma; Bencard Allergy; Boehringer Ingelheim Pharmaceuticals, Inc.; Infectopharm; Novartis Pharmaceuticals Corporation; VitalAir

Editor

Gillian Griffith, BA (Mod), MA

Medical Education Director, WebMD Global, LLC

Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.

Wilma Guerra, BA

Medical Education Director, WebMD Global, LLC

Disclosure: Wilma Guerra, BA, has disclosed no relevant financial relationships.

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact CME@medscape.net

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing “Edit Your Profile” at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing “Edit Your Profile” at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

GAA Interasma

Interasma Global Asthma Association